"Read a recent report saying that the longer BP keeps potential...

"Read a recent report saying that the longer BP keeps potential competing drugs in the clinical in combo with their drugs the better for them to develop own/similar drugs in-house and not have to buy-out or in-license the likes of Immutep. P3 trials could be the death knoll."

this is where Marc and Immutep have been smart imo @Hodgie28 by simply engaging in supply only agreements with Merck
in Combo trials......

Efti's mechanism of action is still largely controlled in house and a broader research scope is only inhibited by funds, the potential
of efti's influence on the immune system in general is yet to be established.....

IMO Merck is more interested in maintaining their cash cow's market dominence and thus I believe there will be a licence
deal done with them as per immuteps targeted patent strategy but no more as I see immutep having a long plan with efti..

but that's just me, in reality I have no idea..